Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, today announced that it has retained Hayden IR, a national investor relations consulting firm, to implement a strategic investor relations program grounded in best practices. Hayden IR will work to raise Plandai’s visibility within the investment community by strengthening its relationships and increasing awareness with the goal of ultimately enhancing shareholder value.
“We are encouraged by our development and recent traction we have made over the past few months and believe we are well positioned to penetrate market opportunities and ramp our sales in the animal phytogenics premixes, dietary supplements and diabetes industries,” said Callum Cottrell-Duffield, Plandai’s Chief Operating Officer. “The available opportunities within our targeted markets have increased and created a solid pipeline of projects. As we look to return to an active reporting status with the SEC, the Board and management believed it was an appropriate time to retain a more proactive strategic investor relations firm to help us reach new potential investors and effectively communicate our investment thesis. We are confident that throughout their national footprint, Hayden IR will help us more effectively communicate our accelerated growth strategy, business objectives and corporate milestones to a wider audience of sophisticated investors.”
Hayden IR is a highly regarded investor relations consulting firm known for its ability to connect under-followed and undervalued emerging growth companies with sophisticated institutional investors, buy-side and sell-side analysts, retail brokerage firms and accredited individual investors. Leveraging decades of cumulative experience, Hayden IR develops strategies to help clients effectively communicate with the investment community and works to increase their exposure through targeted outreach and transparent positioning. Hayden IR helps public companies deliver the right message to the right audience. Over time, Hayden IR helps its clients navigate up the Wall Street value chain and to help them secure a reasonable valuation by broadening their audience, expanding institutional ownership and ensuring clear, consistent communication with the public.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company’s products include animal phytogenics premixes, dietary supplements, and inhibiting diabetes. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: https://www.plandaibiotech.com
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company’s filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.